Novartis Ag (NVS) Accounts Payables (2016 - 2025)
Historic Accounts Payables for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to $4.5 billion.
- Novartis Ag's Accounts Payables fell 253.72% to $4.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.5 billion, marking a year-over-year decrease of 253.72%. This contributed to the annual value of $4.5 billion for FY2025, which is 253.72% down from last year.
- Per Novartis Ag's latest filing, its Accounts Payables stood at $4.5 billion for Q4 2025, which was down 253.72% from $4.6 billion recorded in Q3 2025.
- In the past 5 years, Novartis Ag's Accounts Payables registered a high of $5.6 billion during Q4 2021, and its lowest value of $3.9 billion during Q3 2023.
- Moreover, its 5-year median value for Accounts Payables was $4.7 billion (2021), whereas its average is $4.7 billion.
- Its Accounts Payables has fluctuated over the past 5 years, first tumbled by 2513.82% in 2024, then soared by 1145.09% in 2025.
- Quarter analysis of 5 years shows Novartis Ag's Accounts Payables stood at $5.6 billion in 2021, then fell by 7.33% to $5.1 billion in 2022, then fell by 4.28% to $4.9 billion in 2023, then dropped by 7.19% to $4.6 billion in 2024, then fell by 2.54% to $4.5 billion in 2025.
- Its Accounts Payables stands at $4.5 billion for Q4 2025, versus $4.6 billion for Q3 2025 and $4.5 billion for Q2 2025.